Billiontoone (NASDAQ:BLLN) Issues Earnings Results

Billiontoone (NASDAQ:BLLN) posted its earnings results on Wednesday. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33, Zacks reports. The company’s revenue for the quarter was up 83.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.39) EPS.

Here are the key takeaways from Billiontoone’s conference call:

• Q1 financials were strong — revenue grew 84% YoY to $108.4M with 44% test volume growth, a 73% gross margin, 16% GAAP operating margin, and $537M cash, delivering profitability and positive cash flow.
• Market access and pricing momentum — BillionToOne is now in‑network with Anthem and UnitedHealthcare, reaching ~300 million contracted lives, and ASPs rose 28% YoY to $571, prompting raised 2026 revenue guidance to $450–$465M.
• Product differentiation — the launch of Unity Confirm, the company’s non‑invasive fetal cell–based confirmation assay, showed initial 100% concordance versus invasive diagnostics and is positioned to strengthen Unity as a frontline prenatal offering.
• Oncology ramp shows momentum (oncology revenue nearly 5x to $10.7M and tumor‑naive MRD on track), but longer‑term upside depends on achieving Medicare coverage for Northstar Response and scaling to improve oncology margins.
• Near‑term limits and risks — BillionToOne expects Unity Confirm to address only ~0.5–1% of patients (so minimal direct revenue), its prospective concordance study may take 1–3 years, and accounts receivable rose due to new payer contracts, which could affect short‑term cash conversion.

Billiontoone Trading Up 1.9%

Shares of NASDAQ:BLLN traded up $1.50 during trading on Wednesday, reaching $81.40. The stock had a trading volume of 716,203 shares, compared to its average volume of 473,833. Billiontoone has a one year low of $61.96 and a one year high of $138.70. The firm has a market cap of $3.74 billion and a P/E ratio of 387.62. The company has a debt-to-equity ratio of 0.12, a current ratio of 11.69 and a quick ratio of 11.32. The stock has a 50-day moving average of $77.51.

Institutional Trading of Billiontoone

A number of institutional investors have recently modified their holdings of the company. Rossby Financial LCC bought a new stake in shares of Billiontoone in the 4th quarter valued at about $25,000. Wells Fargo & Company MN bought a new stake in shares of Billiontoone in the 4th quarter valued at about $76,000. Smartleaf Asset Management LLC bought a new stake in shares of Billiontoone in the 4th quarter valued at about $80,000. T. Rowe Price Investment Management Inc. bought a new stake in shares of Billiontoone in the 4th quarter valued at about $264,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Billiontoone in the 4th quarter valued at about $347,000.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BLLN. Guggenheim cut their target price on shares of Billiontoone from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. BTIG Research cut their target price on shares of Billiontoone from $160.00 to $140.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th. Weiss Ratings reissued a “sell (d)” rating on shares of Billiontoone in a research report on Friday, May 1st. Wall Street Zen raised shares of Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Finally, Wells Fargo & Company cut their target price on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 5th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Billiontoone has a consensus rating of “Moderate Buy” and a consensus price target of $126.71.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.